PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Clinical trials for PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study tests whether a patient's own immune cells, modified to target a protein called CD19 on cancer cells, can safely treat several types of non-Hodgkin lymphoma that have come back or not responded to standard treatments. About 36 adults with relapsed or refrac…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: C. Babis Andreadis • Aim: Disease control
Last updated May 17, 2026 02:00 UTC
-
New drug cocktail aims to tame aggressive lymphoma
Disease control Recruiting nowThis early-stage trial tests whether adding the targeted drug polatuzumab vedotin (with or without another drug, glofitamab) to standard chemotherapy is safe and tolerable for people with untreated, fast-growing B-cell lymphomas. About 56 participants will receive the combination…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug aims to tame CAR-T Therapy's dangerous side effects
Disease control Recruiting nowThis study tests whether the drug emapalumab can prevent severe cytokine release syndrome (CRS), a common and serious side effect of CAR-T cell therapy. It enrolls 28 adults with certain types of relapsed or refractory large B-cell lymphoma who are receiving standard CAR-T treatm…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New drug cocktail shows promise for tough lymphoma
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy (EPOCH-R) is safe and effective for people with aggressive B-cell non-Hodgkin lymphoma. About 18 adults with untreated or minimally treated disease will receive the combination. The goal is to improve c…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
New combo therapy offers hope for rare blood cancer
Disease control Recruiting nowThis study tests whether adding the drug pembrolizumab to standard CAR-T cell therapy can improve outcomes for people with a rare type of lymphoma (PMBCL) that has come back or not responded to prior treatment. About 35 adults will receive the combination and be monitored for 6 m…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New drug SGR-1505 enters human testing for blood cancers
Disease control Recruiting nowThis early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia). The main goals are to check safety, find the best dose, and see how the body handles the drug. Participants must have a confirmed diagnosis and be …
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated May 04, 2026 16:22 UTC
-
CAR-T therapy may undo childhood vaccine immunity, new study warns
Knowledge-focused Recruiting nowThis study looks at whether CAR-T cell therapy reduces the protection that vaccines (like measles, mumps, and rubella) provide in people with multiple myeloma and non-Hodgkin lymphoma. Researchers will measure antibody levels before and after CAR-T treatment in 45 adults. The goa…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Apr 26, 2026 19:35 UTC